Kingdon Capital Management L.L.C. purchased a new stake in SteadyMed Ltd. (NASDAQ:STDY) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 503,140 shares of the company’s stock, valued at approximately $3,170,000. Kingdon Capital Management L.L.C. owned 2.00% of SteadyMed as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Nexthera Capital LP boosted its holdings in shares of SteadyMed by 6,579.5% in the second quarter. Nexthera Capital LP now owns 360,626 shares of the company’s stock valued at $2,272,000 after purchasing an additional 355,227 shares during the period. Hedge funds and other institutional investors own 57.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Kingdon Capital Management L.L.C. Purchases Shares of 503,140 SteadyMed Ltd. (STDY)” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at

SteadyMed Ltd. (STDY) traded down 1.54% during mid-day trading on Friday, reaching $3.20. The company’s stock had a trading volume of 117,146 shares. The firm’s market capitalization is $84.98 million. The company’s 50-day moving average price is $3.36 and its 200 day moving average price is $3.36. SteadyMed Ltd. has a 52 week low of $2.25 and a 52 week high of $4.10.

SteadyMed (NASDAQ:STDY) last posted its quarterly earnings results on Friday, August 11th. The company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.01). The business had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.26 million. SteadyMed had a negative return on equity of 226.48% and a negative net margin of 3,179.76%. On average, equities analysts forecast that SteadyMed Ltd. will post ($1.56) earnings per share for the current fiscal year.

STDY has been the subject of a number of research reports. Zacks Investment Research upgraded SteadyMed from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. ValuEngine lowered SteadyMed from a “hold” rating to a “sell” rating in a report on Friday, September 1st.

SteadyMed Profile

SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH).

Receive News & Ratings for SteadyMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SteadyMed Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.